![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AUM LifeTech's FANA Antisense Oligonucleotide (FANA ASO) RNA silencing approach allows efficient and selective targeting of human FOXP3 at the RNA level, in a highly sequence-specific manner.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 17, 2022
Details:
AUM LifeTech has developed their preclinical pipeline in cancer immunotherapy with a focus on lung cancer using their proprietary RNA targeting technology.
Lead Product(s): Anitisense Oligonucleotides
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021